Mohs Micrographic Surgery (MMS)

LCD Information Document Information Source LCD ID N/A LCD ID L33436 Original ICD-9 LCD ID Not Applicable LCD Title Mohs Micrographic Surgery (MMS) Proposed LCD in Comment Period N/A Source Proposed LCD N/A Original Effective Date For services performed on or after 10/01/2015 Revision Effective Date For services performed on or after 11/16/2023 Revision Ending Date N/A Retirement Date N/A Notice Period Start Date N/A Notice Period End Date N/A CPT codes, descriptions, and other data only are copyright 2025 American Medical Association. All Rights Reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association. Current Dental Terminology © 2025 American Dental Association. All rights reserved. Copyright © 2026, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at ub04@aha.org or 312‐422‐3366. Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates. Issue Issue Description This LCD outlines limited coverage for this service with specific details under Coverage Indications, Limitations and/or Medical Necessity. Issue - Explanation of Change Between Proposed LCD and Final LCD CMS National Coverage Policy Title XVIII of the Social Security Act, §1862(a)(1)(A) allows coverage and payment for only those services that are considered to be reasonable and necessary for the diagnosis and/or treatment of illness or injury or to improve the functioning of a malformed body member.Title XVIII of the Social Security Act, §1862(a)(10) where such expenses are for cosmetic surgery or are incurred in connection therewith, except as required for the prompt repair of accidental injury or for improvement of the functioning of a malformed body member. CMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 16, §120 Cosmetic Surgery Coverage Indications, Limitations, and/or Medical Necessity Medicare will consider reimbursement for Mohs micrographic surgery (MMS) for accepted diagnoses and indications. Current accepted diagnoses and indications are listed in this LCD. The physician performing the MMS must be trained and highly skilled in MMS techniques, and pathology identification. The physician must document in the patient's medical record that the diagnosis is appropriate for MMS and that MMS is the most appropriate choice as the treatment of the particular lesion. Medicare is aware that a biopsy of the skin lesion for which Mohs surgery is planned is necessary in order for the physician to determine the exact nature of the lesion(s) to be removed. Occasionally, that biopsy may need to be done on the same day that the Mohs surgery is planned to be done. No payment will be allowed for the biopsy and pathology of a lesion, which requires removal by the MMS technique, if a biopsy of that lesion has been performed within 60 days prior to MMS. An exception exists when a biopsy has been performed within that period and the biopsy results could not be obtained by the Mohs surgeon using reasonable effort. The clinical record must clearly show that this situation existed. Current accepted diagnoses and indications for MMS are:Basal cell carcinomas, squamous cell carcinomas or basalosquamous cell carcinomas in anatomic locations where they are prone to recur: Central facial areas, nose and temple areas of the face (the so-called "mask area" of the face), which includes the eyebrows and periorbital areas, the superolateral temple areas, and the preauricular and postauricular areas. Lips, cutaneous and vermilion. Eyelids. The entire external ear and ear canal. Other skin lesions: Angiosarcoma of the skin. Keratoacanthoma, recurrent or rapidly growing destructive variants. Dermatofibrosarcoma protuberans. Malignant fibrous histiocytoma. Sebaceous gland carcinoma. Microcystic adnexal carcinoma. Extramammary Paget's disease. Bowenoid papulosis. Merkel cell carcinoma. Bowen's disease (squamous cell carcinoma in situ). Adenoid type of squamous cell carcinoma. Rapid growth in a squamous cell carcinoma. Longstanding duration of a squamous cell carcinoma. Verrucous carcinoma. Atypical fibroxanthoma. Leiomyosarcoma or other spindle cell neoplasms of the skin. Adenoid Cystic carcinoma of the skin. Erythroplasia of Queyrat. Oral and central facial, and paranasal sinus neoplasm. Apocrine carcinoma of the skin. Malignant melanoma or melanoma in situ (facial, auricular, genital and digital) when anatomical or technical difficulties do not allow conventional excision with appropriate margins. Rare, biopsy-proven skin malignancies not otherwise addressed in this section. Basal cell carcinomas, squamous cell carcinomas or basalosquamous cell carcinomas having one or more of the following features:• Are recurrent. • Biopsy proven lesions with aggressive pathology as documented by at least 1 of the following microscopic characteristics: Sclerotic. Fibrosing. Morphea-like. Metatypical/infiltrative/spikey shaped cell groups. Perineural or perivascular invasion. Nuclear pleomorphism. High mitotic activity or superficial multicentric. Located in the following areas: genitalia, digits or nail unit/periungual. Large size (1.0 cm or greater in the non-mask areas of the face and 2.0 cm or greater in other areas). Positive margins on recent excision. Poorly defined borders. Present in the very young (less than 40 years of age). Radiation-induced. In patients with proven difficulty with skin cancers or who are immunocompromised. Basal cell nevus syndrome. Present in an old scar (e.g., Marjolin's ulcer). Associated with xeroderma pigmentosum or difficulty estimating depth of lesion. Laryngeal carcinoma in certain limited clinical situations. Summary of Evidence N/A Analysis of Evidence (Rationale for Determination) N/A

Medicare will consider reimbursement for Mohs micrographic surgery (MMS) for accepted diagnoses and indications. Current accepted diagnoses and indications are listed in this LCD. The physician performing the MMS must be trained and highly skilled in MMS techniques, and pathology identification. The physician must document in the patient's medical record that the diagnosis is appropriate for MMS and that MMS is the most appropriate choice as the treatment of the particular lesion. Medicare is aware that a biopsy of the skin lesion for which Mohs surgery is planned is necessary in order for the physician to determine the exact nature of the lesion(s) to be removed. Occasionally, that biopsy may need to be done on the same day that the Mohs surgery is planned to be done. No payment will be allowed for the biopsy and pathology of a lesion, which requires removal by the MMS technique, if a biopsy of that lesion has been performed within 60 days prior to MMS. An exception exists when a biopsy has been performed within that period and the biopsy results could not be obtained by the Mohs surgeon using reasonable effort. The clinical record must clearly show that this situation existed. Current accepted diagnoses and indications for MMS are: Basal cell carcinomas, squamous cell carcinomas or basalosquamous cell carcinomas in anatomic locations where they are prone to recur: Central facial areas, nose and temple areas of the face (the so-called "mask area" of the face), which includes the eyebrows and periorbital areas, the superolateral temple areas, and the preauricular and postauricular areas. Lips, cutaneous and vermilion. Eyelids. The entire external ear and ear canal. Other skin lesions: Angiosarcoma of the skin. Keratoacanthoma, recurrent or rapidly growing destructive variants. Dermatofibrosarcoma protuberans. Malignant fibrous histiocytoma. Sebaceous gland carcinoma. Microcystic adnexal carcinoma. Extramammary Paget's disease. Bowenoid papulosis. Merkel cell carcinoma. Bowen's disease (squamous cell carcinoma in situ). Adenoid type of squamous cell carcinoma. Rapid growth in a squamous cell carcinoma. Longstanding duration of a squamous cell carcinoma. Verrucous carcinoma. Atypical fibroxanthoma. Leiomyosarcoma or other spindle cell neoplasms of the skin. Adenoid Cystic carcinoma of the skin. Erythroplasia of Queyrat. Oral and central facial, and paranasal sinus neoplasm. Apocrine carcinoma of the skin. Malignant melanoma or melanoma in situ (facial, auricular, genital and digital) when anatomical or technical difficulties do not allow conventional excision with appropriate margins. Rare, biopsy-proven skin malignancies not otherwise addressed in this section. Basal cell carcinomas, squamous cell carcinomas or basalosquamous cell carcinomas having one or more of the following features: • Are recurrent. • Biopsy proven lesions with aggressive pathology as documented by at least 1 of the following microscopic characteristics: Sclerotic. Fibrosing. Morphea-like. Metatypical/infiltrative/spikey shaped cell groups. Perineural or perivascular invasion. Nuclear pleomorphism. High mitotic activity or superficial multicentric. Located in the following areas: genitalia, digits or nail unit/periungual. Large size (1.0 cm or greater in the non-mask areas of the face and 2.0 cm or greater in other areas). Positive margins on recent excision. Poorly defined borders. Present in the very young (less than 40 years of age). Radiation-induced. In patients with proven difficulty with skin cancers or who are immunocompromised. Basal cell nevus syndrome. Present in an old scar (e.g., Marjolin's ulcer). Associated with xeroderma pigmentosum or difficulty estimating depth of lesion. Laryngeal carcinoma in certain limited clinical situations.